Core Viewpoint - China Medical's subsidiary, Sanyo Pharmaceutical, has received approval for a supplemental application for Carboprost injection, which is used in cesarean sections to prevent uterine atony and postpartum hemorrhage [1] Group 1: Approval and Product Details - Sanyo Pharmaceutical has been granted a "Drug Supplement Application Approval Notice" by the National Medical Products Administration for Carboprost injection [1] - The drug is intended for use in selective epidural or spinal anesthesia cesarean sections [1] - The approval allows for a change in the marketing authorization holder to Sanyo Pharmaceutical, while the drug approval number remains unchanged [1] Group 2: Financial and Market Impact - Sanyo Pharmaceutical has invested approximately 3.93 million yuan in this drug project [1] - The projected domestic sales for this drug in 2024 are estimated to be around 201 million yuan [1] - Becoming the marketing authorization holder for this drug enhances the company's product line and is expected to improve its market competitiveness [1]

Core Viewpoint - Yiming Pharmaceutical is planning to change its control amid significant fluctuations in its performance and a critical transition in its main business [1] Financial Performance - In 2023, Yiming Pharmaceutical reported a net profit of 15.39 million yuan, a substantial decrease of 65.14% year-on-year, with a non-recurring net profit of only 1.09 million yuan, down 97.22% year-on-year [2] - The decline in performance is attributed to three main pressures: a sharp drop in sales of cooperative products due to drug procurement policies, goodwill impairment of 18 to 21 million yuan for a subsidiary, and the classification of industry support funds as non-recurring gains [2] - In 2024, the company saw a rebound with a net profit of 45.93 million yuan, an increase of 198.50% year-on-year, and a non-recurring net profit of 18.45 million yuan, up 1579.33% year-on-year, although the actual profit scale remains limited due to a low base in 2023 [3] - In Q1 2025, Yiming Pharmaceutical's revenue was 149 million yuan, a decrease of 7.41% year-on-year, and net profit was 18.79 million yuan, down 32.64% year-on-year, indicating ongoing challenges in its core business [3] Market Position and Challenges - Yiming Pharmaceutical, established in December 2016, focuses on the research, production, and sales of chemical drugs and traditional Chinese medicine, primarily targeting diabetes and cardiovascular diseases [1] - The company is facing severe market challenges for its core products due to frequent policy changes in the pharmaceutical industry and the normalization of centralized procurement [1] - The number of institutional investors in Yiming Pharmaceutical has drastically reduced from 22 at the end of 2024 to just 1 by Q1 2025, reflecting a cautious outlook from professional investors [2]